Stereotaxis, Inc. (NYSE: STXS) and CardioFocus, Inc. announced on October 13, 2025 that the two companies have entered into a collaboration agreement to advance a robotic pulsed‑field ablation (PFA) solution for cardiac arrhythmias. The partnership combines Stereotaxis’ robotic magnetic navigation (RMN) platform with CardioFocus’ Centauri PFA system and the MAGiC robotic ablation catheter.
CardioFocus’ Centauri system is CE‑marked and has treated more than 9,000 patients across Europe, with clinical data reported in over 40 publications. Stereotaxis’ RMN systems have guided procedures in more than 150,000 patients worldwide. The two companies completed extensive bench and preclinical testing, including pivotal studies that demonstrated safe, efficient, and durable lesion delivery in ventricular tissue using the Centauri system paired with the MAGiC catheter.
The collaboration aims to bring the first robotic PFA solution to market by advancing the joint platform to a clinical trial and facilitating regulatory compatibility and commercial availability of both MAGiC and Centauri. The partnership represents a significant step toward expanding Stereotaxis’ product portfolio and addressing a growing demand for non‑thermal ablation technologies in electrophysiology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.